South & Central America Radiopharmaceutical Theranostics Market Forecast to 2028 - Regional Analysis - by Product Type, Radioisotope ; Source, Application ; Indication, and End User

Description

List of Tables

The South & Central America radiopharmaceutical theranostics market was valued at US$ 129.48 million in 2022 and is expected to reach US$ 233.71 million by 2028; it is estimated to register a CAGR of 10.3% from 2022 to 2028.

Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies fuel the South & Central America Radiopharmaceutical Theranostics Market

Radiopharmaceutical therapies (RPTs) involve injecting a particular radioactive drug (such as 200mCi for Lu-177-PSMA and Lu-177-DOTATATE) into all patients undergoing therapy. However, upon injection, the doses delivered to organs and absorbed qualities of drugs show notable variations. Radiopharmaceutical therapies for tumors and normal tissues depend on absorbed doses; however, variations in absorption are difficult to control. A fixed administered dosage results in the undertreatment of patients, possibly leading to cases of dose toxicity. Theranostic digital twins (TDTs) can be employed in the drug development process to overcome such limitations. The TDTs investigate optimal injected radioactive drugs among patients at the sites of injection, along with determining injection intervals and profiles, and suitable combinational radiopharmaceutical therapies. Additionally, TDTs coupled with appropriate computational tools can be used in predictive absorbed radiation dose modeling. Further, TDTs promise zero uncertainties in the clinical results generated, thus acting as a powerful tool for offering truly personalized treatments to patients. Thus, the use of TDTs in personalized radiopharmaceutical therapies provides lucrative opportunities for radiopharmaceutical theranostics market players.

South & Central America Radiopharmaceutical Theranostics Market Overview

The South & Central America radiopharmaceutical theranostics market is segmented into the Argentina, Brazil, and the rest of South & Central America. The market growth in this region is due to the increasing prevalence of cancer and cardiovascular diseases, and presence of supportive government plans. Growing diabetes who are prone to cardiovascular disease is promoting the growth of radiopharmaceutical theranostics market in Brazil. Further, expanding healthcare expenditure in Brazil is boosting the radiopharmaceutical theranostics market.

South & Central America Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Radiopharmaceutical Theranostics Market Segmentation

The South & Central America radiopharmaceutical theranostics market is segmented based on product type, radioisotype, source, application, indication, end user, and country. Based on product type, the South & Central America radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and Positron Emission Tomography (PET) tracers. The Positron Emission Tomography (PET) tracers segment held the largest market share in 2022.

Based on radioisotype, the South & Central America radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.

Based on source, the South & Central America radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.

Based on application, the South & Central America radiopharmaceutical theranostics market is bifurcated into targeted therapeutic [Rx] and Companion Diagnostic [CDx]. The targeted therapeutic [Rx] segment held a larger market share in 2022.

Based on indication, the South & Central America radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.

Based on end user, the South & Central America radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The hospitals segment held the largest market share in 2022.

Based on country, the South & Central America radiopharmaceutical theranostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America radiopharmaceutical theranostics market share in 2022.

Bayer AG; Curium; Telix Pharmaceuticals Ltd.; and Siemens Healthineers are some of the leading companies operating in the South & Central America radiopharmaceutical theranostics market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central Americaradiopharmaceutical theranostics market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South & Central Americaradiopharmaceutical theranostics market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central Americaradiopharmaceutical theranostics market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Product Code: BMIRE00029008

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 South & Central America Radiopharmaceutical Theranostics Market - by Product Type
- 1.3.2 South & Central America Radiopharmaceutical Theranostics Market - by Radioisotope
- 1.3.3 South & Central America Radiopharmaceutical Theranostics Market - by Source
- 1.3.4 South & Central America Radiopharmaceutical Theranostics Market - by Application
- 1.3.5 South & Central America Radiopharmaceutical Theranostics Market - by Indication
- 1.3.6 South & Central America Radiopharmaceutical Theranostics Market - by End User
- 1.3.7 South & Central America Radiopharmaceutical Theranostics Market - by Country

2. South & Central America Radiopharmaceutical Theranostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South & Central America Radiopharmaceutical Theranostics Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 South & Central America PEST Analysis
4.3 Expert's Opinion

5. South & Central America Radiopharmaceutical Theranostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Rising Incidence of Cancer
- 5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
- 5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
- 5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
- 5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis

6. Radiopharmaceutical Theranostics Market - South & Central America Analysis

6.1 South & Central America Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis

7. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type

7.1 Overview
7.2 Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
- 7.2.1 Positron Emission Tomography (PET) Tracers
  - 7.2.1.1 Overview
  - 7.2.1.2 Positron Emission Tomography (PET) Tracers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.2 Beta Emitters
  - 7.2.2.1 Overview
  - 7.2.2.2 Beta Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 7.2.3 Alpha Emitters
  - 7.2.3.1 Overview
  - 7.2.3.2 Alpha Emitters: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

8. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Radioisotope

8.1 Overview
8.2 Radiopharmaceutical Theranostics Market Revenue Share, by Radioisotope 2021 & 2028 (%)
- 8.2.1 Technetium-99
  - 8.2.1.1 Overview
  - 8.2.1.2 Technetium-99: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.2 Gallium-68
  - 8.2.2.1 Overview
  - 8.2.2.2 Gallium-68: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.3 Iodine-131
  - 8.2.3.1 Overview
  - 8.2.3.2 Iodine-131: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.4 Iodine-123
  - 8.2.4.1 Overview
  - 8.2.4.2 Iodine-123: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.5 Fluorine-18 (18F)
  - 8.2.5.1 Overview
  - 8.2.5.2 Fluorine-18 (18F): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.6 Yttrium 90 (Y-90)
  - 8.2.6.1 Overview
  - 8.2.6.2 Yttrium 90 (Y-90): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.7 Lutetium (LU) 177
  - 8.2.7.1 Overview
  - 8.2.7.2 Lutetium (LU) 177: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.8 Copper (CU) 67
  - 8.2.8.1 Overview
  - 8.2.8.2 Copper (CU) 67: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.9 Copper (CU) 64
  - 8.2.9.1 Overview
  - 8.2.9.2 Copper (CU) 64: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 8.2.10 Others
  - 8.2.10.1 Overview
  - 8.2.10.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

9. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Source

9.1 Overview
9.2 Radiopharmaceutical Theranostics Market Revenue Share, by Source 2021 & 2028 (%)
- 9.2.1 Nuclear Reactors
  - 9.2.1.1 Overview
  - 9.2.1.2 Nuclear Reactors: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 9.2.2 Cyclotrons
  - 9.2.2.1 Overview
  - 9.2.2.2 Cyclotrons: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

10. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Application

10.1 Overview
10.2 Radiopharmaceutical Theranostics Market Revenue Share, by Application 2021 & 2028 (%)
- 10.2.1 Targeted Therapeutic (Rx)
  - 10.2.1.1 Overview
  - 10.2.1.2 Targeted Therapeutics (Rx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 10.2.2 Companion Diagnostic (CDx)
  - 10.2.2.1 Overview
  - 10.2.2.2 Companion Diagnostics (CDx): Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

11. South & Central America Radiopharmaceutical Theranostics Market Analysis - by Indication

11.1 Overview
11.2 Radiopharmaceutical Theranostics Market Revenue Share, by Indication 2021 & 2028 (%)
- 11.2.1 Oncology
  - 11.2.1.1 Overview
  - 11.2.1.2 Oncology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.2 Neurology
  - 11.2.2.1 Overview
  - 11.2.2.2 Neurology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.3 Cardiology
  - 11.2.3.1 Overview
  - 11.2.3.2 Cardiology: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.4 Others
  - 11.2.4.1 Overview
  - 11.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

12. South & Central America Radiopharmaceutical Theranostics Market Analysis - by End User

12.1 Overview
12.2 Radiopharmaceutical Theranostics Market Revenue Share, by End User 2021 & 2028 (%)
- 12.2.1 Hospitals
  - 12.2.1.1 Overview
  - 12.2.1.2 Hospitals: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.2 Diagnostic Imaging Centers
  - 12.2.2.1 Overview
  - 12.2.2.2 Diagnostic Imaging Centers: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.3 Academic & Research Institutes
  - 12.2.3.1 Overview
  - 12.2.3.2 Academic & Research Institutes: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
- 12.2.4 Others
  - 12.2.4.1 Overview
  - 12.2.4.2 Others: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)

13. South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Country Analysis

13.1 South & Central America Radiopharmaceutical Theranostics Market
- 13.1.1 Overview
- 13.1.2 South & Central America: Radiopharmaceutical Theranostics Market, by Country, 2021 & 2028 (%)
  - 13.1.2.1 Brazil: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.2.1.1 Overview
    - 13.1.2.1.2 Brazil Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.2.1.3 Brazil Radiopharmaceutical Theranostics Market, by Product type, 2019-2028 (US$ Million)
    - 13.1.2.1.4 Brazil Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.2.1.5 Brazil Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.2.1.6 Brazil Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.2.1.7 Brazil Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.2.1.8 Brazil Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.2.2 Argentina: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.2.2.1 Overview
    - 13.1.2.2.2 Argentina Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.2.2.3 Argentina Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.2.2.4 Argentina Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.2.2.5 Argentina Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.2.2.6 Argentina Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.2.2.7 Argentina Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.2.2.8 Argentina Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)
  - 13.1.2.3 Rest of South & Central America: Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.2.3.1 Overview
    - 13.1.2.3.2 Rest of South & Central America Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
    - 13.1.2.3.3 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Product Type, 2019-2028 (US$ Million)
    - 13.1.2.3.4 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Radioisotope, 2019-2028 (US$ Million)
    - 13.1.2.3.5 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Source, 2019-2028 (US$ Million)
    - 13.1.2.3.6 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Application, 2019-2028 (US$ Million)
    - 13.1.2.3.7 Rest of South & Central America Radiopharmaceutical Theranostics Market, by Indication, 2019-2028 (US$ Million)
    - 13.1.2.3.8 Rest of South & Central America Radiopharmaceutical Theranostics Market, by End User, 2019-2028 (US$ Million)

14. Radiopharmaceutical Theranostics Market - Industry Landscape

14.1 Overview
14.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
14.3 Inorganic Growth Strategies
- 14.3.1 Overview
14.4 Organic Growth Strategies
- 14.4.1 Overview

15. Company Profiles

15.1 Bayer AG
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Curium
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Telix Pharmaceuticals Ltd.
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 Siemens Healthineers AG
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments

16. Appendix

16.1 About The Insight Partners
16.2 Glossary of Terms